Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulinastatin for Treatment of Sepsis With Systemic Inflammatory Response Syndrome
NCT05391789Phase 3Completed
- Sponsor
- Huashan Hospital
- Start
- Nov 2022
- Primary completion
- May 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of ulinastatin in sepsis, Systemic Inflammatory Response Syndrome (SIRS), sponsored by Huashan Hospital. Started Nov 2022; status: completed.
02
Drugs
ulinastatin
03
Conditions
sepsisSystemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on NCT05391789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05391789.